Evotec H1 FY26 adjusted EBITDA loss widens to EUR 42.7 million; revenue drops 19.2% to EUR 300.1 million
Reuters2026/08/13 05:28- Evotec SE revenue fell 19.2% to EUR 300.1 million in H1 2026.
- Adjusted EBITDA loss widened to EUR 42.7 million from a near-breakeven loss a year earlier.
- Net loss widened to EUR 168.6 million, driven by EUR 98.9 million in Horizon-related reorganization costs and a EUR 42.3 million impairment.
- Discovery & Preclinical Development revenue slipped 15.2% to EUR 228.1 million; Just-Evotec Biologics dropped 29.3% to EUR 72.3 million.
- Guidance reaffirmed for 2026 revenue of EUR 570 million to EUR 610 million, adjusted EBITDA of negative EUR 70 million to negative EUR 105 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Kvika appoints Jón Birgir Jónsson as CEO, effective Dec. 1
Crypto prices
More
